Disabling pansclerotic morphea of childhood poses a high risk of chronic ulceration of the skin and squamous cell carcinoma

International Journal of Lower Extremity Wounds

Volumn 6, Issue 4, 2007, Pages 291-298

  Wollina, Uwe ^a,f   Buslau, Michael ^b   Heinig, Birgit ^a   Petrov, Ivailo ^c   Unger, Eleonore ^a   Kyriopoulou, Eugenia ^d   Koch, André ^a   Köstler, Erich ^a   Schönlebe, Jaqueline ^a   Haroske, Gunther ^a   Doede, Thorsten ^e   Pramatarov, Kyrill ^c  

^a ACADEMIC TEACHING HOSPITAL DRESDEN FRIEDRICHSTADT   (Germany)

^b Kantonsspital Schaffhausen ^*  (Switzerland)

^c MEDICAL UNIVERSITY OF SOFIA   (Bulgaria)

^d UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^e FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^f DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

Chronic (leg) ulcers; Deep morphoea; Disabling pansclerotic morphoea of childhood; Sildenafil; Squamous cell carcinoma; Tissue engineered skin substitutes

Indexed keywords

ANTIINFECTIVE AGENT; CHLORHEXIDINE; CYCLOSPORIN A; GENTAMICIN; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; METHOXSALEN; PENICILLAMINE; PENICILLIN G; PENTOXIFYLLINE; PREDNISOLONE; SILDENAFIL; STEROID;

ABSENCE OF SIDE EFFECTS; ADOLESCENT; ADULT; ANAMNESIS; ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL FEATURE; COMPRESSION THERAPY; COMPUTER ASSISTED TOMOGRAPHY; DEATH; DISABLING PANSCLEROTIC MORPHEA OF CHILDHOOD; DISEASE COURSE; DOPPLER FLOWMETRY; ELECTROCARDIOGRAM; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GANGRENE; HIGH RISK PATIENT; HOSPITALIZATION; HUMAN; IMMOBILIZATION; JOINT CONTRACTURE; KINESIOTHERAPY; LEG COMPRESSION; LEG ULCER; MALE; MEDICAL LITERATURE; MORPHEA; OCCUPATIONAL THERAPY; PHYSICAL EXAMINATION; PHYSIOTHERAPY; PRIORITY JOURNAL; PUVA; SCLERODERMA; SCLEROSIS; SEPSIS; SKIN BIOPSY; SKIN CANCER; SKIN ULCER; SMALL INTESTINE; SQUAMOUS CELL CARCINOMA; TISSUE ENGINEERING; TRANSCUTANEOUS NERVE STIMULATION; TREATMENT OUTCOME; WOUND;

ADOLESCENT; ADULT; CARCINOMA, SQUAMOUS CELL; CHRONIC DISEASE; COLLAGEN; COMBINED MODALITY THERAPY; CONTRACTURE; FEMALE; HUMANS; MALE; PIPERAZINES; PURINES; SCLERODERMA, LOCALIZED; SKIN NEOPLASMS; SKIN ULCER; SKIN, ARTIFICIAL; SULFONES; VASODILATOR AGENTS;

EID: 36249024807     PISSN: 15347346     EISSN: 15526941     Source Type: Journal    
DOI: 10.1177/1534734607308731     Document Type: Article

References (30)

1. Black CM Scleroderma and fasciitis in children. Curr Opin Rheumatol 1995 ; 7: 442-8.
2. Zulina F., Athreya BH, Laxer R., Nelson AM, Feitosa de Oliveira SK, Punaro MG, et al. Juvenile localized scleroderma: clinical and epidemiological features in 750 children. An international study. Rheumatology 2006 ; 45: 614-20.
3. Chung L., Lin J., Furst DE, Fiorentino D. Systemic and localized scleroderma. Clin Dermatol 2006 ; 24: 374-92.
4. Diaz-Perez JL, Connolly SM, Winkelmann RK Disabling pansclerotic morphea of children. Arch Dermatol 1980 ; 116: 169-73.
5. Wollina U., Heinig B., Uhlemann C. Transdermal CO2 application in chronic wounds. Int J Lower Extremity Wounds 2004 ; 3: 103-6.
6. Tausche A-K., Skaria M., Böhlen L., Liebold K., Hafner J., Friedlein H., et al. An autologous epidermal equivalent tissue-engineered from follicular outer root sheath keratinocytes is as effective as split-thickness skin autograft in recalcitrant vascular leg ulcers. Wound Rep Reg 2003 ; 11: 248-52.
7. Wollina U., Looks A., Uhlemann C., Wollina K. Pansclerotic morphoea of childhood-follow-up over 6 years. Pediatr Dermatol 1999 ; 16: 245-7.
8. Rowell NR Acral pansclerotic morphea with intractable pain. In: Wilkinson DS, Mascaró JM, Orfanos CE, editors. Clinical dermatology-the CMD case collection. Stuttgart: Schattauer ; 1987. p. 178-80.
9. Hafner J., Truëb RM Management of leg ulcers in rheumatoid arthritis and systemic sclerosis. Curr Probl Dermatol 1999 ; 27: 271-6.
10. Fries R., Shariat K., von Wilmowsky H., Böhm M. Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy. Circulation 2005 ; 112: 2980-5.
11. Yung A., Reay N., Goodfield MD Improvement in digital flexibility and dexterity following ingestion of sildenafil citrate (viagra) in limited systemic sclerosis. Arch Dermatol 2005 ; 141: 831-3.
12. Cavorsi J., Vicari F., Wirthlin DJ, Ennis W., Kirsner R., O'Connell SM, et al. Best-practise algorithms for the use of a bilayered living cell therapy (Apligraf) in the treatment of lower-extremity ulcers. Wound Repair Reg 2006 ; 14: 102-9.
13. Bello YM, Falabella AF, Eaglstein WH Tissue-engineered skin. Current status in wound healing. Am J Clin Dermatol 2001 ; 2: 305-13.
14. Mostow EN, Haraway GD, Dalsing M., Hodde JP, King D., OASIS Venus Ulcer Study Group. Effectiveness of an extracellular matrix graft (OASIS Wound Matrix) in the treatment of chronic leg ulcers: a randomized clinical trial. J Vasc Surg 2005 ; 41: 837-43.
15. Niezgoda JA, Van Gils CC, Frykberg RG, Hodde JP Randomized clinical trial comparing OASIS Wound Matrix to Regranex Gel for diabetic ulcers. Adv Skin Wound Care 2005 ; 18: 258-66.
16. Romanelli M., Dini V., Bertone M., Barbanera S., Brilli C. OASIS wound matrix versus Hyaloskin in the treatment of difficult-to-heal wounds of mixed arterial/venous aetiology. Int Wound J 2007 ; 4: 3-7.
17. Wollina U. Increased risk of cancer in scleroderma: no risk in patients with morphoea? Ann Rheum Dis 2003 ; 62: 611-2.
18. Levi F., Moeckli R., Randimbison L., Te VC, Maspoli M., La Vecchia C. Skin cancer in survivors of childhood and adolescent cancer. Eur J Cancer 2006 ; 42: 656-9.
19. Pearce MS, Parker L., Cotterill SJ, Gordon PM, Craft AW Skin cancer in children and young adults: 28 years' experience from the Northern Region Young Person's Malignant Disease Registry, UK. Melanoma Res 2003 ; 13: 421-6.
20. Serafini P., Meckel K., Kelso M., Noonan K., Califano J., Koch W., et al. Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function. J Exp Med 2006 ; 27: 2691-702.
21. Ferrandiz C., Henkes J., González J., Peyri J. Incapacitating pansclerotic morphea in childhood. Med Cutan Ibero Lat Am 1981 ; 9: 377-82.
22. Scharfetter-Kochanek K., Goldermann R., Lehmann P., Hölzle E., Goerz G. PUVA therapy in disabling morphoea of children. Br J Dermatol 1995 ; 132: 830-1.
23. Todd DJ, Askari A., Ektaisch E. PUVA therapy for disabling pansclerotic morphoea of children. Br J Dermatol 1998 ; 138: 201-2.
24. Stücker M., Schreiber D., Gruss C., Freitag M., von Kobyletzki G., Kerscher M., et al. Schwerer Verlauf einer pansklerotischen zirkumskripten Sklerodermie im Kindesalter. Klinik und Therapie. Hautarzt 1999 ; 50: 131-5.
25. Nguyen XH, Hansen R., Valencia F. Severe ankle deformity secondary to pansclerotic morphea in a 9-year-old girl: correction involving arthrodesis and free flap coverage. Pediatr Dermatol 2002 ; 19: 560-3.
26. Nagai Y., Hattori T., Ishikawa O. Unilateral generalized morphea in childhood. J Dermatol 2002 ; 29: 435-8.
27. Singh DS, Kumar L., Radotra BD Disabling morphea of childhood and hypogammaglobulinemia: a curios association. Rheumatol Int 2002 ; 21: 158-60.
28. Yildirim M., Baysal V., Aridogan BC, Kesici D., Erturan I. Pansclerotic morphea treated with UVA: a case report. J Dermatol 2003 ; 30: 625-7.
29. Kawashima H., Watanabe C., Kashiwagi Y., Sato S., Ioi H., Sasamoto M., et al. Therapy of childhood generalized morphea: case reports and reviews of the literature of Japanese cases. Pediatr Int 2006 ; 48: 342-8.
30. Roldan R., Morote G., Castro M del C, Miranda MD, Moreno JC, Collantes E. Efficacy of bosentan in treatment of unresponsive cutaneous ulceration in disabling morphea in children. J Rheumatol 2006 ; 33: 2538-40.